ASCO’s CancerLinQ launches SmartLinQ QOPI Certification Pathway

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ASCO’s CancerLinQ launched the SmartLinQ QOPI Certification Pathway, an application that allows oncology practices to automate quality measure tracking and reporting for participation in ASCO’s Quality Oncology Practice Initiative Certification Program, a three-year certification recognizing practices’ commitment to high-quality care for outpatient oncology practices.

Since 2019, SmartLinQ has enabled CancerLinQ practices to automate their quality activities, derive actionable insights from real-world patient data, and benchmark their care against the CancerLinQ network. The new SmartLinQ QOPI Certification Pathway was recently piloted at four of CancerLinQ’s more than 100 subscribing practices, enabling them to reduce staff time and expenses for quality reporting for QOPI Certification. It is now available for re-certification and maintenance submissions for all QOPI Certified CancerLinQ subscribers.

SmartLinQ’s benefits stem from the automation of quality management functions, beginning with data collection. CancerLinQ automatically and securely takes in and harmonizes and codifies the data from practices’ electronic health record systems, eliminating the need for manual chart abstraction for quality programs like QOPI Certification. New Mexico Cancer Center, one of the SmartLinQ QOPI Certification Pathway pilot practices, saved approximately 100 hours of staff time when using SmartLinQ to automate its recertification for the QOPI Certification Program.

Beyond data abstraction and automated quality reporting for QOPI Certification, SmartLinQ enables practices to:

  • Track progress daily against a broad set of quality measures, both for the practice overall and for specific sites and individual physicians

  • Benchmark care against peers, by querying de-identified patient data on 1.5 million real-world cancer patient records in the CancerLinQ database

  • Identify “actionable patients” who still need specific care or treatment to comply with quality standards, creating opportunities to proactively improve care

  • Identify and fix data quality issues, such as missing or inaccurate data in patients’ EHRs.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login